{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T10:58:26Z","timestamp":1772276306780,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s11102-020-01097-1","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T03:03:06Z","timestamp":1603076586000},"page":"207-215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Corticotroph tumor progression during long-term therapy with osilodrostat\u00a0in a patient with persistent Cushing\u2019s disease"],"prefix":"10.1007","volume":"24","author":[{"given":"C\u00e9dric","family":"Fontaine-Sylvestre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"L\u00e9tourneau-Guillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Moumdjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"France","family":"Berthelet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-3025","authenticated-orcid":false,"given":"Andr\u00e9","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"issue":"9996","key":"1097_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/s0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing\u2019s syndrome. Lancet 386(9996):913\u2013927. https:\/\/doi.org\/10.1016\/s0140-6736(14)61375-1","journal-title":"Lancet"},{"issue":"10","key":"1097_CR2","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1210\/jc.2014-1843","volume":"99","author":"M Fleseriu","year":"2014","unstructured":"Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C (2014) Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab 99(10):3718\u20133727. https:\/\/doi.org\/10.1210\/jc.2014-1843","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1097_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/s2213-8587(18)30155-4","volume":"7","author":"RA Feelders","year":"2019","unstructured":"Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A (2019) Advances in the medical treatment of Cushing\u2019s syndrome. Lancet Diabetes Endocrinol 7(4):300\u2013312. https:\/\/doi.org\/10.1016\/s2213-8587(18)30155-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1097_CR4","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A (2015) Treatment of cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807\u20132831. https:\/\/doi.org\/10.1210\/jc.2015-1818","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1097_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of cushing\u2019s disease. Endocr Rev 36(4):385\u2013486. https:\/\/doi.org\/10.1210\/er.2013-1048","journal-title":"Endocr Rev"},{"issue":"1","key":"1097_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1210\/jc.2006-1328","volume":"92","author":"G Assi\u00e9","year":"2007","unstructured":"Assi\u00e9 G, Bahurel H, Coste J, Silvera S, Kujas M, Dugu\u00e9 MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing\u2019s Disease: A reappraisal of Nelson\u2019s Syndrome. J Clin Endocrinol Metab 92(1):172\u2013179. https:\/\/doi.org\/10.1210\/jc.2006-1328","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1097_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1530\/eje-07-0514","volume":"158","author":"F Castinetti","year":"2008","unstructured":"Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease. Eur J Endocrinol 158(1):91\u201399. https:\/\/doi.org\/10.1530\/eje-07-0514","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1097_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/eje-12-0358","volume":"167","author":"C Baudry","year":"2012","unstructured":"Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J, Abbas H, Legmann P, Bertagna X, Bertherat J (2012) Efficiency and tolerance of mitotane in Cushing\u2019s disease in 76 patients from a single center. Eur J Endocrinol 167(4):473\u2013481. https:\/\/doi.org\/10.1530\/eje-12-0358","journal-title":"Eur J Endocrinol"},{"key":"1097_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30240-0","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O\u2019Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(20)30240-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1097_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1365-2265.2009.03756.x","volume":"73","author":"C Jung","year":"2010","unstructured":"Jung C, Alford FP, Topliss DJ, Burgess JR, Long F, Gome JJ, Stockigt JR, Inder WJ (2010) The 4-mg intravenous dexamethasone suppression test in the diagnosis of Cushing\u2019s syndrome. Clin Endocrinol (Oxf) 73(1):78\u201384. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03756.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1097_CR11","doi-asserted-by":"publisher","first-page":"R201","DOI":"10.1530\/eje-18-0007","volume":"178","author":"DA Vassiliadi","year":"2018","unstructured":"Vassiliadi DA, Tsagarakis S (2018) DIAgnosis of endocrine disease: the role of the desmopressin test in the diagnosis and follow-up of Cushing\u2019s syndrome. Eur J Endocrinol 178(5):R201-r214. https:\/\/doi.org\/10.1530\/eje-18-0007","journal-title":"Eur J Endocrinol"},{"key":"1097_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111951","author":"H Nishioka","year":"2019","unstructured":"Nishioka H, Yamada S (2019) Cushing\u2019s disease. J Clin Med. https:\/\/doi.org\/10.3390\/jcm8111951","journal-title":"J Clin Med"},{"issue":"2","key":"1097_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1210\/js.2017-00036","volume":"1","author":"AB Grossman","year":"2017","unstructured":"Grossman AB (2017) The molecular pathology of cushing disease: are we nearly there? J Endocr Soc 1(2):144\u2013148. https:\/\/doi.org\/10.1210\/js.2017-00036","journal-title":"J Endocr Soc"},{"issue":"5","key":"1097_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-020-01277-0","volume":"80","author":"S Duggan","year":"2020","unstructured":"Duggan S (2020) Osilodrostat: first approval. Drugs 80(5):495\u2013500. https:\/\/doi.org\/10.1007\/s40265-020-01277-0","journal-title":"Drugs"},{"issue":"2","key":"1097_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","volume":"19","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, Tanaka T, Shimatsu A, White T, Hilliard A, Tian C, Sauter N, Biller BM, Bertagna X (2016) Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing\u2019s disease. Pituitary 19(2):138\u2013148. https:\/\/doi.org\/10.1007\/s11102-015-0692-z","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-020-01097-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-020-01097-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-020-01097-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T11:11:44Z","timestamp":1635160304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-020-01097-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1097"],"URL":"https:\/\/doi.org\/10.1007\/s11102-020-01097-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"13 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AL received funding as an investigator for participation in the LINC-3 trial from Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"LINC-3 study was approved by the CHUM ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patient provided informed signed consent\u00a0to participate in the study and to publish results.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}